Literature DB >> 21652079

Intraocular pressure outcome of patients with fluocinolone acetonide intravitreal implant for noninfectious uveitis.

Kathryn Bollinger1, James Kim, Careen Y Lowder, Peter K Kaiser, Scott D Smith.   

Abstract

PURPOSE: To evaluate the intraocular pressure (IOP) outcomes of patients with noninfectious posterior uveitis treated with a fluocinolone acetonide (FA) intravitreal implant over an 8-year period.
DESIGN: Retrospective clinical case series. PARTICIPANTS: Forty-seven eyes of 35 patients.
METHODS: Retrospective review of medical records of all patients receiving FA implants between June 2001 and March 2009 was performed. Data were pooled to record visual acuity (VA) and to characterize the incidence and outcome of glaucoma surgical intervention. MAIN OUTCOME MEASURES: Incidence of glaucoma surgery and IOP before and after glaucoma surgical intervention. Visual acuity before and after FA implant placement.
RESULTS: Nineteen of 42 eyes (45%) receiving FA implants over the course of the study period required glaucoma surgical intervention. Success of IOP-lowering surgery was achieved in 94%, 94%, and 92% of eyes at 6, 12, and 24 months postoperatively. No patient lost more than 1 line of VA. There was an average 2-line gain of acuity at 3 years after FA implant placement for those patients who underwent IOP-lowering surgery.
CONCLUSIONS: Patients receiving FA implants have a significant risk of increased IOP that frequently necessitates glaucoma surgery. Glaucoma surgery, when necessary, offers an effective method to decrease IOP. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21652079     DOI: 10.1016/j.ophtha.2011.02.042

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  16 in total

1.  Inhibition of neovascularization but not fibrosis with the fluocinolone acetonide implant in autosomal dominant neovascular inflammatory vitreoretinopathy.

Authors:  Paul S Tlucek; James C Folk; Jason A Orien; Edwin M Stone; Vinit B Mahajan
Journal:  Arch Ophthalmol       Date:  2012-11

2.  Statistical design for formulation optimization of hydrocortisone butyrate-loaded PLGA nanoparticles.

Authors:  Xiaoyan Yang; Sulabh Patel; Ye Sheng; Dhananjay Pal; Ashim K Mitra
Journal:  AAPS PharmSciTech       Date:  2014-02-07       Impact factor: 3.246

3.  Postoperative outcomes after fluocinolone acetonide implant surgery in patients with birdshot chorioretinitis and other types of posterior and panuveitis.

Authors:  Bryn M Burkholder; Jiangxia Wang; James P Dunn; Quan D Nguyen; Jennifer E Thorne
Journal:  Retina       Date:  2013-09       Impact factor: 4.256

Review 4.  Animal models of glucocorticoid-induced glaucoma.

Authors:  Darryl R Overby; Abbot F Clark
Journal:  Exp Eye Res       Date:  2015-06-04       Impact factor: 3.467

5.  Development of a novel bioerodible dexamethasone implant for uveitis and postoperative cataract inflammation.

Authors:  Srinivas Rao Chennamaneni; Christina Mamalis; Bonnie Archer; Zack Oakey; Balamurali K Ambati
Journal:  J Control Release       Date:  2013-01-13       Impact factor: 9.776

6.  Triamcinolone acetonide decreases outflow facility in C57BL/6 mouse eyes.

Authors:  Sandeep Kumar; Shaily Shah; Emily Rose Deutsch; Hai Michael Tang; John Danias
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-01       Impact factor: 4.799

7.  Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial.

Authors:  David S Friedman; Janet T Holbrook; Husam Ansari; Judith Alexander; Alyce Burke; Susan B Reed; Joanne Katz; Jennifer E Thorne; Susan L Lightman; John H Kempen
Journal:  Ophthalmology       Date:  2013-04-16       Impact factor: 12.079

Review 8.  Systemic lupus erythematosus and ocular involvement: an overview.

Authors:  Rosanna Dammacco
Journal:  Clin Exp Med       Date:  2017-12-14       Impact factor: 3.984

Review 9.  Corticosteroid implants for chronic non-infectious uveitis.

Authors:  Christopher J Brady; Andrea C Villanti; Hua Andrew Law; Ehsan Rahimy; Rahul Reddy; Pamela C Sieving; Sunir J Garg; Johnny Tang
Journal:  Cochrane Database Syst Rev       Date:  2016-02-12

10.  De novo ocular hypertension after Descemet stripping endothelial keratoplasty: comparative 3-year incidence, risk factors, and outcomes.

Authors:  Errol W Chan; Tina T Wong; Hla M Htoon; Ching L Ho; Donald T Tan; Jodhbir S Mehta
Journal:  Clin Ophthalmol       Date:  2013-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.